Cruz-Jentoff et al. present a valuable review of the difficult field of clinical measurements of sarcopenia [1] . However, several problems remain that limit full acceptance of their calculations. First, all or most of the current methods employed for measurement of muscle mass or fat-free mass (FFM) have associated assumptions and technical issues, and questionable accuracy in assessing small changes [2] . Further, although extensively discussed by the authors, the major current anatomical definitions of sarcopenia are clearly error-prone. Given the very wide variations of muscle mass (about half of FFM) within the normal population, the use of the 'sex-specific lowest 20% of study group' or of '>2 standard deviations below mean of young adults' seem poor definition criteria. For example, using direct measurement of body fat by inert gas absorption to accurately calculate FFM by difference (±2%), the range of FFM for healthy Americans of similar sex, age and height is very wide (over 40%) [3] . Many (most?) bigger normal persons could lose over 20% of FFM (or muscle mass) without being appreciated as sarcopenic while smaller normals might be labelled sarcopenic with only minor loss [3] .
